Related references
Note: Only part of the references are listed.Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial
Jean-Marc Naccache et al.
LANCET RESPIRATORY MEDICINE (2022)
Acute exacerbations of fibrotic interstitial lung diseases
Atsushi Suzuki et al.
RESPIROLOGY (2020)
Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis A Randomized, Double-Blind Placebo-controlled Trial
Yasuhiro Kondoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Diagnosis of Hypersensitivity Pneumonitis in Adults An Official ATS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis
Hironao Hozumi et al.
RESPIROLOGY (2019)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
K. R. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
Motoyasu Kato et al.
SCIENTIFIC REPORTS (2019)
Evaluation and management of Idiopathic Pulmonary Fibrosis
Tomoo Kishaba
RESPIRATORY INVESTIGATION (2019)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Acute exacerbations of progressive-fibrosing interstitial lung diseases
Martin Kolb et al.
EUROPEAN RESPIRATORY REVIEW (2018)
Japanese guideline for the treatment of idiopathic pulmonary fibrosis
Sakae Homma et al.
RESPIRATORY INVESTIGATION (2018)
Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?
Alessandro Marchioni et al.
CRITICAL CARE (2018)
Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials
Arata Azuma et al.
RESPIROLOGY (2017)
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Harold R. Collard et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
Hiromi Tomioka et al.
RESPIROLOGY CASE REPORTS (2017)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report
Harold R. Collard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences
Motoki Natsuizaka et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease
Ryoko Shimizu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis
Keishi Oda et al.
RESPIRATORY RESEARCH (2014)
The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients
Guru Sonpavde et al.
CURRENT ONCOLOGY REPORTS (2012)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
M. Reck et al.
ANNALS OF ONCOLOGY (2011)
Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Isamu Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis
Masanori Akira et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?
A. R. L. Medford et al.
THORAX (2006)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
A Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Share Paper
